Targeting the GTPase RAN by liposome delivery for tackling cancer stemness-emanated therapeutic resistance
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.09.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Kaili Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Jiangsu Key Laboratory of Drug Design and…. Hauptthemen laut MEDLINE: Liposomes, Neoplastic Stem Cells, Drug Resistance, Neoplasm, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China, Fok Ying Tong Education Foundation.
Abstract (Originalsprache)
Cancer therapeutic resistance as a common hallmark of cancer is often responsible for treatment failure and poor patient survival. Cancer stem-like cells (CSCs) are one of the main contributors to therapeutic resistance, cancer relapse and metastasis. Through screening from our in-house library of natural products, we found polyphyllin II (PPII) as a potent anti-CSC compound for triple-negative breast cancer (TNBC). To enhance anti-CSC selectivity and improve druggability of PPII, we leverage the liposome-mediated delivery technique for increasing solubility of PPII, and more significantly, attaining broader therapeutic window. Liposomal PPII demonstrates its marked potency to inhibit tumor growth, post-surgical recurrence and metastasis compared to commercial liposomal chemotherapeutics in the mouse models of CSC-enriched TNBC tumor. We further identify PPII as an inhibitor of the Ras-related nuclear (RAN) protein whose upregulated expression is correlated with poor clinical outcomes. The direct binding of PPII to RAN reduces TNBC stemness, thereby suppressing tumor progression. Our work offers a significance from drug discovery to drug delivery benefiting from liposome technique for targeted treatment of high-stemness tumor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Jiangsu Key Laboratory of Drug Design and Optimization, Center of Advanced Pharmaceuticals and Biomaterials, Sc…
- College of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310032, China.
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Fok Ying Tong Education Foundation
- China Pharmaceutical University
Zitieren
APA
Wang, K., Zhu, S., Zhang, Y., Wang, Y., Bian, Z., Lu, Y., Shao, Q., Jin, X., Xu, X., & Mo, R. (2024). Targeting the GTPase RAN by liposome delivery for tackling cancer stemness-emanated therapeutic resistance. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.09.007
Vancouver
Wang K, Zhu S, Zhang Y, Wang Y, Bian Z, Lu Y, et al. Targeting the GTPase RAN by liposome delivery for tackling cancer stemness-emanated therapeutic resistance. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.09.007
BibTeX
@article{Wang2024,
author = {Wang, Kaili and Zhu, Sitong and Zhang, Ying and Wang, Yuqian and Bian, Zhenqian and Lu, Yougong and Shao, Quanlin and Jin, Xiang and Xu, Xiaojun and Mo, Ran},
title = {Targeting the GTPase RAN by liposome delivery for tackling cancer stemness-emanated therapeutic resistance},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.09.007}
}
EUVIMED